Filing Flows › Madrigal Pharmaceuticals (MDGL) › Q3 2026 › vs Q3 2025
Madrigal Pharmaceuticals (MDGL) Q3 2026 vs Q3 2025 (year over year)
Madrigal Pharmaceuticals's revenue rose $144M (+50%) from $287M in Q3 2025 to $431M in Q3 2026. Operating margin 13.0% against -39.7% (+52.7 pts).
Madrigal Pharmaceuticals, Q3 2026: revenue $431M (+50% year over year), operating margin 13.0%, net earnings $55.4M, operating cash flow $121M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Operating margin | 13.0% | -39.7% | +52.7 pts |
| Net margin | 12.9% | -39.8% | +52.6 pts |
| Free cash flow margin | 27.0% | 27.5% | -0.5 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $431M | $287M | $144M | +50% |
| Operating profit | $56.0M | −$114M | $170M | — |
| Costs & expenses | $375M | $401M | −$26.0M | -6% |
| Pre-tax earnings | $55.4M | −$114M | $170M | — |
| Research & development | $71.8M | $174M | −$102M | -59% |
| SG&A | $266M | $209M | $56.6M | +27% |
| Other operating costs | $37.8M | $18.1M | $19.7M | +109% |
| Net earnings | $55.4M | −$114M | $170M | — |
| Depreciation & amortization | $391K | $358K | $33K | +9% |
| Share-based compensation | $38.9M | $26.3M | $12.7M | +48% |
| Working capital & other | $25.8M | $167M | −$142M | -85% |
| Operating cash flow | $121M | $79.8M | $40.7M | +51% |
| Free cash flow (OCF − capex) | $117M | $79.0M | $37.6M | +48% |
| Capital expenditures | $3.9M | $857K | $3.1M | +358% |
Questions
How much did Madrigal Pharmaceuticals's revenue grow year over year in Q3 2026?
Madrigal Pharmaceuticals's revenue rose $144M (+50%) from $287M in Q3 2025 to $431M in Q3 2026. Operating margin 13.0% against -39.7% (+52.7 pts).